Evidence map›Paper›PMID 40061321›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Trajectories of microbiome-derived bile acids in early life - insights into the progression to islet autoimmunity.

Santosh Lamichhane, Alex M Dickens, Tanja Buchacher, Evita Tianai Lou, Vincent Charron-Lamoureux, Roosa Kattelus, Pragya Karmacharya, Lucas Pinto da Silva, Matilda Kråkström, Omid Rasool and 18 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Santosh LamichhaneTurku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520 Turku, Finland.
Alex M DickensTurku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520 Turku, Finland.
Tanja BuchacherTurku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520 Turku, Finland.
Evita Tianai LouMedical Research Council Laboratory of Medical Sciences (MRC LMS), Imperial College Hammersmith Campus, London, UK.
Vincent Charron-LamoureuxCollaborative Mass Spectrometry Innovation Center, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, CA, USA.
Roosa KattelusTurku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520 Turku, Finland.
Pragya KarmacharyaTurku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520 Turku, Finland.
Lucas Pinto da SilvaTurku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520 Turku, Finland.
Matilda KråkströmTurku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520 Turku, Finland.
Omid RasoolTurku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520 Turku, Finland.
Partho SenTurku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520 Turku, Finland.
Corinn WalkerDepartment of Pediatrics, University of California San Diego, La Jolla, California, USA.
Abubaker PatanCollaborative Mass Spectrometry Innovation Center, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, CA, USA.
Emily C GentryCollaborative Mass Spectrometry Innovation Center, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, CA, USA.
Aron ArzoomandDepartment of women's and children's health, Karolinska Institutet, Stockholm, Sweden.
Tadepally LakshmikanthMedical Research Council Laboratory of Medical Sciences (MRC LMS), Imperial College Hammersmith Campus, London, UK.
Jaromir MikešDepartment of women's and children's health, Karolinska Institutet, Stockholm, Sweden.
Aman MebrahtuMedical Research Council Laboratory of Medical Sciences (MRC LMS), Imperial College Hammersmith Campus, London, UK.
Tommi VatanenResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Finland.
Manuela RaffatelluFaculty of Agriculture and Forestry, University of Helsinki, Helsinki, Finland.
Karsten ZenglerDepartment of Pediatrics, University of California San Diego, La Jolla, California, USA.
Tuulia HyötyläinenSchool of Science and Technology, Örebro University, Örebro, Sweden.
Ramnik J XavierThe Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Petter BrodinMedical Research Council Laboratory of Medical Sciences (MRC LMS), Imperial College Hammersmith Campus, London, UK.
Riitta LahesmaaTurku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520 Turku, Finland.
Pieter C DorresteinCollaborative Mass Spectrometry Innovation Center, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, CA, USA.
Mikael KnipResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Finland.
Matej OrešičTurku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520 Turku, Finland.

Funding

Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
The impact of ampicillin and breast milk oligosaccharides on the infant microbiome and immune functionsP50HD106463 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Lars Bode, CHRISTINA CHAMBERS · 2021 to 2026
$19.6M
Identification and Characterization of Microbial Metabolites in ImmunityR01AI172147 · NIAID · BROAD INSTITUTE, INC. · PI Daniel Bartholomew Graham, Ramnik J Xavier · 2022 to 2026
$3.9M
Collaborative Microbial Metabolite CenterU24DK133658 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PIETER C DORRESTEIN · 2022 to 2026
$2.9M
Reverse Metabolomics for the Discovery of Disease Associated Microbial MoleculesR01DK136117 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PIETER C DORRESTEIN · 2023 to 2026
$2.9M
NIAID NIH HHS R01 AI172147NICHD NIH HHS P50 HD106463NIDDK NIH HHS P30 DK043351NIDDK NIH HHS R01 DK136117NIDDK NIH HHS U24 DK133658
6 · The paper itself

Abstract

Recent studies reveal that gut microbes produce diverse bile acid conjugates, termed microbially conjugated bile acids (MCBAs). However, their regulation and health effects remain unclear. Here, we analyzed early-life MCBA patterns and their link to islet autoimmunity. We quantified 110 MCBAs in 303 stool samples collected longitudinally (3-36 months) from children who developed one or more islet autoantibodies and controls who remained autoantibody-negative. Stool MCBAs showed distinct age-dependent trajectories and correlated with gut microbiome composition. Altered levels of ursodeoxycholic and deoxycholic acid conjugates were linked to islet autoimmunity as well as modulated monocyte activation in response to immunostimulatory lipopolysaccharide and Th17/Treg cell balance. These findings suggest MCBAs influence immune development and type 1 diabetes risk.

Identifiers

PMID40061321
PMCPMC11888530

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.